• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

针对免疫检查点的小分子药物的研发。

Development of small molecule drugs targeting immune checkpoints.

机构信息

Department of Oncology, Sichuan Academy of Medical Sciences, Sichuan Provincial People's Hospital, School of Medicine, University of Electronic Science and Technology of China, Chengdu 610054, China.

Institute for Breast Health Medicine, State Key Laboratory of Biotherapy, West China Hospital, Sichuan University, Chengdu 610041, China.

出版信息

Cancer Biol Med. 2024 May 9;21(5):382-99. doi: 10.20892/j.issn.2095-3941.2024.0034.

DOI:10.20892/j.issn.2095-3941.2024.0034
PMID:38727005
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11131045/
Abstract

Immune checkpoint inhibitors (ICIs) are used to relieve and refuel anti-tumor immunity by blocking the interaction, transcription, and translation of co-inhibitory immune checkpoints or degrading co-inhibitory immune checkpoints. Thousands of small molecule drugs or biological materials, especially antibody-based ICIs, are actively being studied and antibodies are currently widely used. Limitations, such as anti-tumor efficacy, poor membrane permeability, and unneglected tolerance issues of antibody-based ICIs, remain evident but are thought to be overcome by small molecule drugs. Recent structural studies have broadened the scope of candidate immune checkpoint molecules, as well as innovative chemical inhibitors. By way of comparison, small molecule drug-based ICIs represent superior oral bioavailability and favorable pharmacokinetic features. Several ongoing clinical trials are exploring the synergetic effect of ICIs and other therapeutic strategies based on multiple ICI functions, including immune regulation, anti-angiogenesis, and cell cycle regulation. In this review we summarized the current progression of small molecule ICIs and the mechanism underlying immune checkpoint proteins, which will lay the foundation for further exploration.

摘要

免疫检查点抑制剂(ICIs)通过阻断共抑制免疫检查点的相互作用、转录和翻译或降解共抑制免疫检查点来缓解和增强抗肿瘤免疫。成千上万的小分子药物或生物材料,特别是基于抗体的 ICIs,正在积极研究中,并且抗体目前被广泛应用。基于抗体的 ICIs 的局限性,如抗肿瘤疗效、较差的膜通透性和被忽视的耐受性问题仍然很明显,但人们认为小分子药物可以克服这些问题。最近的结构研究拓宽了候选免疫检查点分子的范围,以及创新的化学抑制剂。相比之下,基于小分子药物的 ICIs 具有更好的口服生物利用度和良好的药代动力学特征。目前正在进行几项临床试验,以探索基于多种 ICI 功能(包括免疫调节、抗血管生成和细胞周期调节)的 ICIs 和其他治疗策略的协同作用。在这篇综述中,我们总结了小分子 ICIs 的最新进展和免疫检查点蛋白的作用机制,为进一步探索奠定了基础。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1167/11131045/a0ac9f607452/cbm-21-382-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1167/11131045/a0ac9f607452/cbm-21-382-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1167/11131045/a0ac9f607452/cbm-21-382-g001.jpg

相似文献

1
Development of small molecule drugs targeting immune checkpoints.针对免疫检查点的小分子药物的研发。
Cancer Biol Med. 2024 May 9;21(5):382-99. doi: 10.20892/j.issn.2095-3941.2024.0034.
2
Biphenyl-based small molecule inhibitors: Novel cancer immunotherapeutic agents targeting PD-1/PD-L1 interaction.联苯小分子抑制剂:靶向 PD-1/PD-L1 相互作用的新型癌症免疫治疗药物。
Bioorg Med Chem. 2022 Nov 1;73:117001. doi: 10.1016/j.bmc.2022.117001. Epub 2022 Sep 13.
3
If small molecules immunotherapy comes, can the prime be far behind?如果小分子免疫疗法问世,佐剂能落后吗?
Eur J Med Chem. 2021 Jun 5;218:113356. doi: 10.1016/j.ejmech.2021.113356. Epub 2021 Mar 11.
4
Immunomodulatory Precision: A Narrative Review Exploring the Critical Role of Immune Checkpoint Inhibitors in Cancer Treatment.免疫调节精准度:探索免疫检查点抑制剂在癌症治疗中关键作用的叙述性综述。
Int J Mol Sci. 2024 May 17;25(10):5490. doi: 10.3390/ijms25105490.
5
Immune checkpoints and cancer development: Therapeutic implications and future directions.免疫检查点与癌症发生:治疗意义与未来方向
Pathol Res Pract. 2021 Jul;223:153485. doi: 10.1016/j.prp.2021.153485. Epub 2021 May 15.
6
The importance of immune checkpoints in immune monitoring: A future paradigm shift in the treatment of cancer.免疫检查点在免疫监测中的重要性:癌症治疗的未来范式转变。
Biomed Pharmacother. 2022 Feb;146:112516. doi: 10.1016/j.biopha.2021.112516. Epub 2021 Dec 11.
7
Advances and clinical applications of immune checkpoint inhibitors in hematological malignancies.免疫检查点抑制剂在血液系统恶性肿瘤中的研究进展及临床应用
Cancer Commun (Lond). 2024 Sep;44(9):1071-1097. doi: 10.1002/cac2.12587. Epub 2024 Jul 28.
8
Current state and future of co-inhibitory immune checkpoints for the treatment of glioblastoma.免疫检查点抑制剂在胶质母细胞瘤治疗中的现状与未来
Cancer Biol Med. 2020 Aug 15;17(3):555-568. doi: 10.20892/j.issn.2095-3941.2020.0027.
9
Anti-angiogenic Agents in Combination With Immune Checkpoint Inhibitors: A Promising Strategy for Cancer Treatment.抗血管生成药物联合免疫检查点抑制剂:癌症治疗的一种有前途的策略。
Front Immunol. 2020 Aug 25;11:1956. doi: 10.3389/fimmu.2020.01956. eCollection 2020.
10
Non-coding RNA and immune-checkpoint inhibitors: friends or foes?非编码 RNA 与免疫检查点抑制剂:是敌是友?
Immunotherapy. 2020 May;12(7):513-529. doi: 10.2217/imt-2019-0204. Epub 2020 May 7.

引用本文的文献

1
Negative Immune Checkpoint Inhibitors.阴性免疫检查点抑制剂
Pharmaceutics. 2025 May 28;17(6):713. doi: 10.3390/pharmaceutics17060713.
2
Immune checkpoint inhibitors in cancer therapy: what lies beyond monoclonal antibodies?癌症治疗中的免疫检查点抑制剂:单克隆抗体之外还有什么?
Med Oncol. 2025 Jun 19;42(7):273. doi: 10.1007/s12032-025-02822-1.
3
Nano drug delivery systems for advanced immune checkpoint blockade therapy.用于先进免疫检查点阻断疗法的纳米药物递送系统

本文引用的文献

1
Benzosceptrin C induces lysosomal degradation of PD-L1 and promotes antitumor immunity by targeting DHHC3.苯并色烯 C 通过靶向 DHHC3 诱导 PD-L1 的溶酶体降解并促进抗肿瘤免疫。
Cell Rep Med. 2024 Feb 20;5(2):101357. doi: 10.1016/j.xcrm.2023.101357. Epub 2024 Jan 17.
2
Peptide drugs: a new direction in cancer immunotherapy.肽类药物:癌症免疫治疗的新方向。
Cancer Biol Med. 2023 Dec 7;21(3):198-203. doi: 10.20892/j.issn.2095-3941.2023.0297.
3
Identification of a small-molecule Tim-3 inhibitor to potentiate T cell-mediated antitumor immunotherapy in preclinical mouse models.
Theranostics. 2025 Apr 13;15(11):5440-5480. doi: 10.7150/thno.112475. eCollection 2025.
在临床前小鼠模型中鉴定一种小分子Tim-3抑制剂以增强T细胞介导的抗肿瘤免疫疗法。
Sci Transl Med. 2023 Nov 15;15(722):eadg6752. doi: 10.1126/scitranslmed.adg6752.
4
Nanomedicine-based co-delivery of a calcium channel inhibitor and a small molecule targeting CD47 for lung cancer immunotherapy.基于纳米医学的钙通道抑制剂和靶向 CD47 的小分子共递用于肺癌免疫治疗。
Nat Commun. 2023 Nov 11;14(1):7306. doi: 10.1038/s41467-023-42972-2.
5
GcForest-based compound-protein interaction prediction model and its application in discovering small-molecule drugs targeting CD47.基于GcForest的化合物-蛋白质相互作用预测模型及其在发现靶向CD47的小分子药物中的应用。
Front Chem. 2023 Oct 20;11:1292869. doi: 10.3389/fchem.2023.1292869. eCollection 2023.
6
Artificial intelligence in small molecule drug discovery from 2018 to 2023: Does it really work?2018 年至 2023 年小分子药物发现中的人工智能:它真的有效吗?
Bioorg Chem. 2023 Dec;141:106894. doi: 10.1016/j.bioorg.2023.106894. Epub 2023 Sep 27.
7
Virtual Screening and Biological Evaluation of Potential PD-1/PD-L1 Immune Checkpoint Inhibitors as Anti-Hepatocellular Carcinoma Agents.潜在的PD-1/PD-L1免疫检查点抑制剂作为抗肝细胞癌药物的虚拟筛选及生物学评价
ACS Omega. 2023 Sep 3;8(37):33242-33254. doi: 10.1021/acsomega.3c00279. eCollection 2023 Sep 19.
8
Artificial intelligence for natural product drug discovery.人工智能在天然产物药物发现中的应用。
Nat Rev Drug Discov. 2023 Nov;22(11):895-916. doi: 10.1038/s41573-023-00774-7. Epub 2023 Sep 11.
9
Discovery of Small-Molecule TIM-3 Inhibitors for Acute Myeloid Leukemia Using Pharmacophore-Based Virtual Screening.基于药效团的虚拟筛选发现用于急性髓细胞白血病的小分子 TIM-3 抑制剂。
J Med Chem. 2023 Aug 24;66(16):11464-11475. doi: 10.1021/acs.jmedchem.3c00960. Epub 2023 Aug 11.
10
Dual-Pronged Attack: pH-Driven Membrane-Anchored NIR Dual-Type Nano-Photosensitizer Excites Immunogenic Pyroptosis and Sequester Immune Checkpoint for Enhanced Prostate Cancer Photo-Immunotherapy.双管齐下的攻击:pH 驱动的膜锚定近红外双模式纳米光敏剂激发免疫原性细胞焦亡并隔离免疫检查点以增强前列腺癌光免疫治疗。
Adv Sci (Weinh). 2023 Oct;10(28):e2302422. doi: 10.1002/advs.202302422. Epub 2023 Aug 6.